Acta Med. 2000, 43: 75-82

https://doi.org/10.14712/18059694.2019.117

Anthracycline-Induced Cardiotoxicity

Radomír Hrdinaa, Vladimír Geršlb, Ivona Klimtováa, Tomáš Šimůneka, Jarmila Macháčkováb, Michaela Adamcovác

aCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology and Toxicology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Physiology, Hradec Králové, Czech Republic

Received May 1, 2000
Accepted June 1, 2000

References

1. Adamcová M, Geršl V, Hrdina R et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. Cancer Res Clin Oncol 1999; 125:268-74.
2. al-Shabanah O, Mansour M, el-Kashef H, al-Bekairi AM. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem Mol Biol Int 1998; 45:419-27.
3. al-Shabanah OA, Badary OA, Nagi MN, al-Gharably MN, al-Rikabi AC, al-Bekairi AM. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exp Clin Cancer Res 1998; 17:193-8.
4. Arai M, Tomaru K, Takizawa T et al. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 1998; 30:243-54. <https://doi.org/10.1006/jmcc.1997.0588>
5. Bocherens-Gadient SA, Quast U, Nussberger J, Brunner HR, Hof RP. Chronic adriamycin treatment and its effect on the cardiac β-adrenergic system in the rabbit. J Cardiovasc Pharmacol 1992; 19:770-8.
6. Bright JM, Buss DD. Effects of verapamil on chronic doxorubicin-induced cardiotoxicity in dogs. J Natl Cancer Inst 1990; 82:963-4. <https://doi.org/10.1093/jnci/82.11.963>
7. Cao Y, Kennedy R, Klimberg VS. Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res 1999; 85:178-82. <https://doi.org/10.1006/jsre.1999.5677>
8. Cini-Neri G, Neri B, Bandinelli M, Del-Tacca M, Danesi R, Riccardi R. Anthracycline cardiotoxicity: In vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat. Oncol Schwitzerland 1991; 48:327-33. <https://doi.org/10.1159/000226952>
9. Cottin Y, Touzery C, Dalloz F et al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998; 21:665-70. <https://doi.org/10.1002/clc.4960210911> <PubMed>
10. Coudray C, Boucher F, Deleiris J, Favier A. Modulation by selenium supplementation of lipid peroxidation induced by chronic administration of adriamycin in rats. Nutrition 1995; 11(suppl 5):512-6.
11. Creighton AM, Hellmann K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969; 222:384-5. <https://doi.org/10.1038/222384a0>
12. Ewer MS, Jaffe N, Ried H, Zietz HA, Benjamin RS. Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol 1998; 31:512-5. <https://doi.org/10.1002/(SICI)1096-911X(199812)31:6<512::AID-MPO8>3.0.CO;2-4>
13. Ferrans VJ, Clark JR, Zhang J, Yu ZX, Herman EH. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 1997; 39:928-37.
14. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53:461-70. <https://doi.org/10.1159/000227621>
15. Geršl V, Bajgar J, Hrdina R et al. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits. Gen Physiol Biophys 1999; 18:335-46.
16. Geršl V, Hrdina R. Noninvasive polygraphic cardiac changes in daunorubicin induced cardiomyopathy in rabbits. Sb Ved Pr Lek Fak Univerzity Karlovy Hradec Králové 1994; 37:49-55.
17. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-41. <https://doi.org/10.1016/S0006-2952(98)00307-4>
18. Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 1997; 23:775-82. <https://doi.org/10.1016/S0891-5849(97)00025-7>
19. Halali-Rutman I, Herschko C, Link G, Rutman AJ, Shainberg A. Inhibition of calcium accumulation by the sarcoplasmic reticulum: A putative mechanism for the cardiotoxicity of adriamycin. Biochem Pharmacol 1997; 54:211-4. <https://doi.org/10.1016/S0006-2952(97)00108-1>
20. Hashimoto I, Ichida F, Miura M et al. Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancy. Circulation 1999; 99:2367-70. <https://doi.org/10.1161/01.CIR.99.18.2367>
21. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5:1-28.
22. Herman EH, Ferrans VJ. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest 1983; 49:69-77.
23. Herman EH, Ferrans VJ. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 1998; 25(suppl 10):15-21.
24. Herman EH, Lipshultz SE, Rifai N et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 1998; 58:195-7.
25. Hershko Ch, Pinson A, Link G. Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematol 1996; 95:87-92. <https://doi.org/10.1159/000203954>
26. Hochster H, Liebes L, Wadler S et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992; 84:1725-30. <https://doi.org/10.1093/jnci/84.22.1725>
27. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54 (suppl 4):1-7. <https://doi.org/10.2165/00003495-199700544-00003>
28. Hoyano Y, Furukawa Y, Oguchi T, Kasama M, Imamura H, Chiba S. Acute presynaptic inhibition by doxorubicin of negative chrono- and inotropic responses to parasympathetic nerve stimulation in isolated, blood-perfused dog atrium. J Cardiovasc Pharmacol 1996; 27:37-41. <https://doi.org/10.1097/00005344-199601000-00007>
29. Chopra S, Pillai KK, Husain SZ, Giri DK. Propolis protects against doxorubicininduced myocardiopathy in rats. Exp Mol Pathol 1995; 62:190-8. <https://doi.org/10.1006/exmp.1995.1021>
30. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmac Ther 1990; 47:219-31. <https://doi.org/10.1016/0163-7258(90)90088-J>
31. Klugmann FB, Decorti G, Candusio L et al. Amelioration of 4’-epidoxorubicininduced cardiotoxicity by sodium cromoglycate. Eur J Cancer Clin Oncol 1989; 25:361-8. <https://doi.org/10.1016/0277-5379(89)90031-X>
32. Klugmann FB, Decorti G, Candussio L, Grill V, Mallardi F, Baldini L. Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo. Br J Cancer 1986; 54:743-8. <https://doi.org/10.1038/bjc.1986.235> <PubMed>
33. Lenk MK, Zeybek C, Okutan V, Ozcan O, Gokcay E. Detection of early anthracycline- induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. Turk J Pediatr 1998; 40:373-83.
34. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 1996; 127:272-8. <https://doi.org/10.1016/S0022-2143(96)90095-5>
35. Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996; 14:328-31. <https://doi.org/10.1200/JCO.1996.14.2.328>
36. Luo X, Evrovsky Y, Cole D, Trines J, Benson LN, Lehotay DC. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochim Biophys Acta 1997; 1360:45-52.
37. Luo X, Reichetzer B, Trines J, Benson LN, Lehotay DC. L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats. Free Radic Biol Med 1999; 26:1158-65. <https://doi.org/10.1016/S0891-5849(98)00303-7>
38. Marx JJM, van Asbeck BS. Use of iron chelators in preventing hydroxyl radical damage: Adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol 1996; 95:49-62. <https://doi.org/10.1159/000203949>
39. Mazué G, Williams GM, Iatropoulos MJ et al. Anthracyclines: Review of genotoxicity and carcinogenicity studies. Int J Oncol 1996; 8:525-36.
40. Mazzarello GP, Morra L. Anthracyclines and the heart. Recenti Prog Med 1998; 89:459-64 (abstract).
41. Miwa N, Kanaide H, Meno H, Nakamura M. Adriamycin and altered membrane functions in rat hearts. Br J Exp Path 1986; 67:747-55.
42. Morishima I, Matsui H, Mukawa H et al. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci 1998; 63:511-21. <https://doi.org/10.1016/S0024-3205(98)00302-6>
43. Nagami K, Yoshikawa T, Suzuki M, Wainai Y, Anzai T, Handa S. Abnormal betaadrenergic transmembrane signaling in rabbits with adriamycin-induced cardiomyopathy. Jpn Circ J 1997; 61:249-55. <https://doi.org/10.1253/jcj.61.249>
44. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart H. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 1999; 43:227-32. <https://doi.org/10.1007/s002800050888>
45. Nielsen OS, Dombernowsky P, Mouridsen H et al. High-dose epirubicin is not an altervative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998; 78:1634-9. <https://doi.org/10.1038/bjc.1998.735> <PubMed>
46. Nohl H, Gille L, Staniek K. The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch 1998; 53:279-85. <https://doi.org/10.1515/znc-1998-3-419>
47. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vulteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’slym phoma. Eur J Haematol 1999; 62:135-41. <https://doi.org/10.1111/j.1600-0609.1999.tb01734.x>
48. Nowak D, Drzewoski J. Anthracycline-induced oxidative stress - its role in the development of cardiac damage. Cancer J 1996; 9:296-303.
49. Pouna P, Bonoronadele S, Gouverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996; 117:1593-9. <https://doi.org/10.1111/j.1476-5381.1996.tb15326.x> <PubMed>
50. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity. Cancer Res 1988; 48:4766-9.
51. Reynolds JEF,ed. Martindale The Extra Pharmacopoiea. 31st ed. London: Royal Pharmaceutical Society,1996:567-70.
52. Santostasi G, Kutty RK, Krishna G. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes. Toxicol Appl Pharmacol 1991; 108:140-9. <https://doi.org/10.1016/0041-008X(91)90277-L>
53. Seifert CF, Thompson DF, Nesser ME. Dexrazoxane in the prevention of doxorubicin- induced cardiotoxicity. Ann Pharmacother 1994; 28:1063-72. <https://doi.org/10.1177/106002809402800912>
54. Serrano J, Palmeira CM, Kuehl DW, Wallace KB. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1999; 1411:201-5. <https://doi.org/10.1016/S0005-2728(99)00011-0>
55. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 study group. J Clin Oncol 1999; 17:1435-41. <https://doi.org/10.1200/JCO.1999.17.5.1435>
56. Suarato A, Angelucci F, Geroni C. Ring-B modified anthracyclines. Curr Pharm Des 1999; 5:217-27.
57. Suzuki J, Yanagisawa A, Shigeyama T, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology 1999; 50:37-45. <https://doi.org/10.1177/000331979905000105>
58. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136:362-3. <https://doi.org/10.1053/hj.1998.v136.89908>
59. Tjeerdsma G, Meinardi MT, van Der Graaf WT et al. Early detection of anthracycline- induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81:419-23. <https://doi.org/10.1136/hrt.81.4.419> <PubMed>
60. Towart R, Jynge P, Refsum H, Karlsson JOG. Manganese dipyridoxyl diphosphate protects against anthracycline-induced cardiotoxicity in mice. Naunyn-Schmiedeberg’s Arch Pharmacol 1998; 358 (suppl 1):R626 (abstract).
61. van Acker SABE, Voest EE, Beems DB et al. Cardioprotective properties of O-(β- hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. Cancer Res 1993; 53:4603-7.
62. van Vleet JF, Ferrans VJ. Evaluation of vitamin E and selenium protection against chronic adriamycin toxicity in rabbits. Cancer Treat Rep 1980; 64:315-7.
63. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 1998; 124:425-7. <https://doi.org/10.1038/sj.bjp.0701877> <PubMed>
64. von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-7. <https://doi.org/10.7326/0003-4819-91-5-710>
65. Weiss G, Loyevsky M, Gordeuk VR. Dexrazoxane (ICRF-187). Gen Pharmacol 1999; 32:155-8. <https://doi.org/10.1016/S0306-3623(98)00100-1>
66. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 1992; 19:670-86.
67. Wexler LH, Andrich MP, Venzon D et al. Randomized trial of the cardioprotective agent ICFR-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14:362-72. <https://doi.org/10.1200/JCO.1996.14.2.362>
68. Working PK, Newman MS, Sullivan T, Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther 1999; 289:1128-33.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive